A recent preclinical study demonstrated that the inhibition of IL-17, using either a monoclonal antibody or a small-molecule IL-17 blocker, effectively elevated glucocorticoid sensitivity in steroid-resistant neutrophilic airway inflammation [85]. Here, IL17A is linked to inflammation.